Clin2
NCT03159364Possibly a fitTerminated

Immune cells for viral infections after transplant

Pathogen InfectionEBV InfectionCMV InfectionAdenovirus InfectionBKV InfectionFungus InfectionTuberculosis

Part of Infections clinical trials.

This trial tests whether specially grown immune cells (T cells) can fight common viruses like CMV, EBV, or BK virus in people with weakened immune systems, such as after a stem cell or organ transplant. It may help when standard medicines don't work or can't be used.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
100 people
Ages
6 months to 80 years
Study type
Interventional

Who can take part

  • You have a current infection with CMV, EBV, ADV, BKV virus that isn't responding to medicine or can't be treated with standard drugs.
  • Your virus levels are high or you have symptoms like fever, diarrhea, or swollen glands.
  • Your blood cell counts have started to recover after a transplant (neutrophils ≥ 500, platelets ≥ 20,000).
  • Your kidney and liver function are fairly good (creatinine, bilirubin, and liver enzymes within 2-3 times the upper normal limit).
  • If the immune cells come from a donor, that donor must be healthy and free of HIV, hepatitis B/C, and tuberculosis.
  • You haven't had other experimental cell therapies in the last 30 days, and you are not pregnant.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07685457Recruiting
Virus-specific T cells for stubborn viral infections after transplant

This trial tests whether specially trained immune cells (virus-specific T cells) can safely treat stubborn viral infections after a stem cell transplant. It focuses on children and young adults who have not responded to standard antiviral treatments.

Seoul
NCT02007356Recruiting· Phase 2
Donor immune cell infusions for viral infections after stem cell transplant

This trial studies whether directly infusing donor-made immune cells (virus-fighting T-cells) is safe and feasible in people who still have viral infections after a stem cell transplant. It may help your body control infections from adenovirus, CMV, or EBV when standard antiviral treatments aren’t working.

Basel
NCT07670468Recruiting· Phase 1/Phase 2
T-cell therapy for resistant viral infections after transplant or cancer treatment

This trial tests a special T-cell treatment (LB-DTK-MV) for people with virus infections (CMV, BKV, EBV) that did not get better with standard medicines. It is for patients who had a stem cell transplant or certain cancer therapies like CAR-T or bispecific antibodies.

Seoul
NCT04832607Recruiting· Phase 3
Donor T-cell treatment for stubborn CMV, EBV, or Adenovirus after transplant

This Phase 3 trial tests giving special immune cells from your stem-cell donor to treat difficult-to-control viral infections after a stem cell transplant. It may help your body fight the virus when standard antiviral medicines haven’t worked well enough.

Brussels
NCT06909110Recruiting· Phase 1/Phase 2
Immune cells for viral infections after transplant

This trial tests a treatment using specially trained immune cells (virus-specific T-cells) to fight stubborn infections with adenovirus, CMV, or EBV in people with weakened immune systems, such as after a stem cell or organ transplant.

Palo Alto, California
NCT06027879Enrolling by invitation· Phase 1/Phase 2
Anti-viral T-cell therapy for stubborn viral infections after transplant

This trial tests a treatment using specially grown T-cells (a type of immune cell) to fight certain viruses that won't go away with standard medicines. It is for people who have had a stem cell or organ transplant, or who have a weak immune system, and who are struggling with adenovirus, CMV, or EBV infections.

Pittsburgh, Pennsylvania

Hear when a new EBV Infection trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.